Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

0.8800
-0.0240-2.65%
Pre-market: 0.88000.00000.00%08:00 EST
Volume:69.40K
Turnover:61.60K
Market Cap:29.14M
PE:-2.33
High:0.9098
Open:0.9090
Low:0.8700
Close:0.9040
52wk High:2.60
52wk Low:0.6801
Shares:33.11M
Float Shares:22.11M
Volume Ratio:0.23
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3778
EPS(LYR):-0.5489
ROE:-2478.16%
ROA:-303.90%
PB:-56.15
PE(LYR):-1.60

Loading ...

NeuroSense files to sell 333K ordinary shares for holders

TIPRANKS
·
Oct 29, 2025

Neurosense Therapeutics Ltd : Noble Capital Initiates Coverage With Outperform Rating; Target Price $9

THOMSON REUTERS
·
Oct 14, 2025

NeuroSense announces ‘positive’ results from Phase-2b PARADIGM study

TIPRANKS
·
Oct 06, 2025

Neurosense Therapeutics Ltd -Primec Produces Statistically Significant Reductions in Alzheimer’s Disease Biomarkers

THOMSON REUTERS
·
Oct 06, 2025

NeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer’s Disease Biomarkers

Reuters
·
Oct 06, 2025

NeuroSense Therapeutics Ltd. Held Annual General Meeting of Shareholders

Reuters
·
Sep 25, 2025

BRIEF-Neurosense's Drug Candidate Shows Early Signals Of Benefit In Alzheimer's Patient-Derived Neurons

Reuters
·
Sep 11, 2025

NeuroSense Therapeutics Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease

Reuters
·
Sep 11, 2025

Neurosense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

THOMSON REUTERS
·
Sep 11, 2025

Neurosense Therapeutics- Initial Phase 2 Road Trial Results Demonstrate Improvements in Brain-Cell Connectivity Health, With Favorable Safety Profile

THOMSON REUTERS
·
Sep 11, 2025

NeuroSense Therapeutics Announces Promising Phase 2b PARADIGM Study Results Showing Significant Survival Advantage for ALS Drug PrimeC

Reuters
·
Sep 04, 2025

Press Release: NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Dow Jones
·
Sep 04, 2025

Neurosense Therapeutics Ltd: Statistically Significant Effect at 18 Months (P=0.03) Demonstrated by Nfl-Adjusted Mmrm Analysis

THOMSON REUTERS
·
Sep 02, 2025

Neurosense Therapeutics Ltd: New Analysis of 18-Month Data From Its Phase 2B Paradigm Study of Primec in ALS

THOMSON REUTERS
·
Sep 02, 2025

Neurosense Therapeutics : Analysis, Adjusted for Baseline Nfl Confirms That Observed Benefit Is Consistent After Accounting for Patient Variability

THOMSON REUTERS
·
Sep 02, 2025

NeuroSense Therapeutics Announces Positive 18-Month Data from Phase 2b PARADIGM Study of PrimeC in ALS

Reuters
·
Sep 02, 2025